ABSTRACT
Most lymphomas and multiple myeloma (MM) are malignancies resulting from the unrestrained clonal
proliferation of B-cells at different stages of maturation. For nearly two decades, the International Lymphoma
Epidemiology (InterLymph) Consortium has systematically uncovered genetic and non-genetic lymphoma
and MM risk factors. We aim to build upon nearly 20 years of successful collaboration within the InterLymph
Consortium to undertake the largest genome-wide association study (GWAS) of lymphomas and MM to date,
to assess the performance of polygenic risk scores for lymphomas, and to identify gene-environment
interactions associated with disease susceptibility. This will address key questions: specifically, can we fully
elucidate the genetic variants involved in susceptibility MM, HL, and NHL subtypes? How do the genetic
profiles overlap? How do these profiles interact with the environmental risk factors? With further precision,
can factors be combined to assist in risk prediction? In Aim 1, we will undertake the largest genome wide
association study (GWAS) to date of ~60,000 lymphoma cases, including HL (N=~6,700), NHL
(N=~36,000) and MM (N=~16,000) and over 197,000 controls. In Aim 2, we will develop polygenic risk
scores (PRS), including conducting a validation of the PRS in an independent series of 13,700 lymphoma
patients. In Aim 3, we will evaluate GWAS and subtype-specific PRS in the context of select
environmental exposure data to gain novel insight into exposure-disease relationships and potentially
uncover novel susceptibility loci which act only in the presence of specific environmental triggers. Finally, in
Aim 4, we will create a platform hub for the InterLymph Consortium. This platform, called the Data
Coordinating Center (DCC), will ensure that the field's most pertinent, cutting edge hypothesis driven
research questions can be applied within the resources of the InterLymph Consortium. Through this project,
we aim to activate the collective intelligence and resources of the InterLymph researchers in order to expand
our understanding of how genetic variants and the environment influence risk of lymphomas and explore how
this may assist clinical practice.
